RT Journal Article SR Electronic T1 Treatment Outcome of the Combination Therapy of High-dose rate Intracavitary Brachytherapy and Intensity-modulated Radiation Therapy With Central-shielding for Cervical Cancer JF In Vivo JO In Vivo FD International Institute of Anticancer Research SP 3387 OP 3398 DO 10.21873/invivo.12177 VO 34 IS 6 A1 YUKI MUKAI A1 YUMIKO MINAGAWA A1 HIROMI INOUE A1 AKIKO SATO A1 KENGO MATSUI A1 TAKANORI FUKUDA A1 KAZUYA ONUMA A1 HIDEYUKI HONGO A1 RYOSUKE SHIRATA A1 HIRONORI NAGATA A1 HARUMITU HASHIMOTO A1 TOMIO INOUE A1 MASAHARU HATA A1 MOTOKO OMURA YR 2020 UL http://iv.iiarjournals.org/content/34/6/3387.abstract AB Background/Aim: This study aimed to evaluate the clinical outcome of intensity-modulated radiation therapy (IMRT) and high-dose-rate intracavitary brachytherapy (HDR-ICBT) in uterine cervical cancer (UCC). IMRT consisted of whole-pelvic radiation therapy (WPRT) and sequential WPRT with central-shielding (WPRT-CS). Patients and Methods: Thirty UCC patients treated with IMRT using TomoTherapy, were retrospectively analyzed. Results: The median dose of WPRT and WPRT-CS was 36 and 14.4 Gy and the median total dose of these was 50 Gy in 25 fractions (Fr). Median HDR-ICBT dose/Fr to Point A was 25 Gy/5 Fr. Median 2 Gy per fraction-equivalent dose (EQD2) of combined WPRT and HDR-ICBT to Point A (α/β=10) was 71.0 Gy. The 3-year local control, disease-free survival, and overall survival rates were 89.9%, 83.3%, and 86.3%. Conclusion: IMRT of WPRT and WPRT-CS given in combination with HDR-ICBT was a feasible therapy resulting in good disease control and tolerance in patients with UCC.